A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

January 29, 2027

Study Completion Date

November 19, 2028

Conditions
Neoplasms
Interventions
DRUG

BI 765179

BI 765179

DRUG

Ezabenlimab

Ezabenlimab

DRUG

Pembrolizumab

Pembrolizumab

Trial Locations (50)

1200

RECRUITING

Cliniques Universitaires Saint-Luc, Brussels

2010

RECRUITING

Kinghorn Cancer Centre, Darlinghurst

2640

COMPLETED

Border Cancer Hospital, Albury

2650

NOT_YET_RECRUITING

Edegem - UNIV UZ Antwerpen, Edegem

3084

RECRUITING

Austin Hospital, Heidelberg

4814

NOT_YET_RECRUITING

Townsville Hospital, Douglas

8500

RECRUITING

Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk

13496

NOT_YET_RECRUITING

CHA Bundang Medical Center, Seongnam

14080

RECRUITING

Instituto Nacional de Cancerologia, México

21079

RECRUITING

CTR Georges-François Leclerc, Dijon

21565

NOT_YET_RECRUITING

Gachon University Gil Medical Center, Incheon

27514

NOT_YET_RECRUITING

The University of North Carolina at Chapel Hill, Chapel Hill

28040

RECRUITING

Hospital Clínico San Carlos, Madrid

31008

RECRUITING

Clínica Universidad de Navarra, Pamplona

33075

NOT_YET_RECRUITING

HOP Saint-André, Bordeaux

44805

NOT_YET_RECRUITING

INS Cancérologie Ouest Saint-Herblain, Saint-Herblain

45070

NOT_YET_RECRUITING

Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de C.V., Zapopan

57105

NOT_YET_RECRUITING

Avera Cancer Institute, Sioux Falls

64460

NOT_YET_RECRUITING

Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey

65653

NOT_YET_RECRUITING

Masaryk Memorial Cancer Institute, Brno

66278

NOT_YET_RECRUITING

Fundación Santos y de la Garza Evia, I.B.P, Monterrey

70174

RECRUITING

Klinikum Stuttgart, Stuttgart

78229

COMPLETED

NEXT Oncology-San Antonio-65273, San Antonio

79106

RECRUITING

Universitätsklinikum Freiburg, Freiburg im Breisgau

80131

COMPLETED

Istituto Nazionale IRCCS Tumori Fondazione Pascale, Napoli

85719

RECRUITING

University of Arizona, Tucson

90211

RECRUITING

Beverly Hills Cancer Center, Beverly Hills

233004

NOT_YET_RECRUITING

The First Affiliated Hospital Of Bengbu Medical College, Bengbu

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

410013

NOT_YET_RECRUITING

Hunan Province Tumor Hospital, Changsha

430022

RECRUITING

Wuhan Union Hospital, Wuhan

510095

NOT_YET_RECRUITING

Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou

6423906

NOT_YET_RECRUITING

Sourasky Medical Center, Tel Aviv

9103102

NOT_YET_RECRUITING

Shaare-Zedek Medical Center, Oncology Institute, Jerusalem

01246-000

RECRUITING

ICESP - Instituto do Cancer do Estado de Sao Paulo, São Paulo

01308050

RECRUITING

Hospital Sírio Libanês-São Paulo-68088, São Paulo

01321-001

RECRUITING

Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo

06120

NOT_YET_RECRUITING

Martin-Luther-Universität Halle-Wittenberg, Halle

464-8681

RECRUITING

Aichi Cancer Center Hospital, Aichi, Nagoya

277-8577

RECRUITING

National Cancer Center Hospital East, Chiba, Kashiwa

241-8515

NOT_YET_RECRUITING

Kanagawa Cancer Center, Kanagawa, Yokohama

573-1191

NOT_YET_RECRUITING

Kansai Medical University Hospital, Osaka, Hirakata

541-8567

RECRUITING

Osaka International Cancer Institute, Osaka, Osaka

04700

NOT_YET_RECRUITING

Centro Oncologico Internacional, Mexico City

06700

NOT_YET_RECRUITING

ARKE SMO S.A. de C.V, Mexico City

1081HV

RECRUITING

VU University Medical Center, Amsterdam

3015 GD

NOT_YET_RECRUITING

Erasmus Medisch Centrum-ROTTERDAM-50697, Rotterdam

05505

RECRUITING

Asan Medical Center, Seoul

08916

RECRUITING

Hospital Germans Trias i Pujol, Badalona

08035

RECRUITING

Hospital Universitari Vall D Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04958239 - A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Biotech Hunter | Biotech Hunter